PRNewswire (Tue, 21-Apr 10:15 AM ET)
IDEAYA Biosciences Sets April 13 for Major Metastatic Uveal Melanoma Trial Update: What to Watch
Market Chameleon (Mon, 13-Apr 6:46 AM ET)
IDEAYA's Darovasertib Combo Shows Significant Advantage in Phase 2/3 Uveal Melanoma Trial
Market Chameleon (Mon, 13-Apr 4:25 AM ET)
PRNewswire (Mon, 13-Apr 6:00 AM ET)
PRNewswire (Fri, 10-Apr 4:05 PM ET)
PRNewswire (Mon, 6-Apr 6:00 AM ET)
IDEAYA Pivots to Global Phase 1 Combo Study: Early Signs Point to Synergy in Tumor Treatment
Market Chameleon (Mon, 30-Mar 3:31 AM ET)
PRNewswire (Mon, 30-Mar 6:00 AM ET)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PRNewswire (Fri, 27-Mar 6:00 AM ET)
PRNewswire (Sun, 22-Mar 10:00 AM ET)
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Ideaya Biosciences trades on the NASDAQ stock market under the symbol IDYA.
As of April 23, 2026, IDYA stock price declined to $30.70 with 1,208,220 million shares trading.
IDYA has a beta of 1.19, meaning it tends to be more sensitive to market movements. IDYA has a correlation of 0.13 to the broad based SPY ETF.
IDYA has a market cap of $2.70 billion. This is considered a Mid Cap stock.
Last quarter Ideaya Biosciences reported $11 million in Revenue and -$.94 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.04.
In the last 3 years, IDYA traded as high as $47.74 and as low as $13.45.
The top ETF exchange traded funds that IDYA belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWN.
IDYA has outperformed the market in the last year with a return of +64.8%, while the SPY ETF gained +35.8%. However, in the most recent history, IDYA shares have underperformed the stock market with its stock returning -15.2% in the last 3 month period and -0.8% for the last 2 week period, while SPY has returned +3.1% and +4.8%, respectively.
IDYA support price is $30.48 and resistance is $32.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IDYA shares will trade within this expected range on the day.
